Northera Confirmatory Trial Could Recruit Patients From Expanded Access Program
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA was unreceptive to Chelsea’s proposal to change endpoint in on-going 306B study to provide confirmatory efficacy data for droxidopa in neurogenic orthostatic hypotension.